vs

Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and Hut 8 Corp. (HUT). Click either name above to swap in a different company.

BIOCRYST PHARMACEUTICALS INC is the larger business by last-quarter revenue ($156.4M vs $88.5M, roughly 1.8× Hut 8 Corp.). On growth, Hut 8 Corp. posted the faster year-over-year revenue change (179.2% vs 7.5%). Over the past eight quarters, Hut 8 Corp.'s revenue compounded faster (30.8% CAGR vs 19.6%).

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

Tropical Hut is a Filipino chain of fast food restaurants owned by Mercury Group of Companies, Inc. It is the 7th oldest food chain in the Philippines and older than Jollibee (1978) and McDonald's Philippines (1981).

BCRX vs HUT — Head-to-Head

Bigger by revenue
BCRX
BCRX
1.8× larger
BCRX
$156.4M
$88.5M
HUT
Growing faster (revenue YoY)
HUT
HUT
+171.7% gap
HUT
179.2%
7.5%
BCRX
Faster 2-yr revenue CAGR
HUT
HUT
Annualised
HUT
30.8%
19.6%
BCRX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BCRX
BCRX
HUT
HUT
Revenue
$156.4M
$88.5M
Net Profit
$-279.7M
Gross Margin
60.4%
Operating Margin
13.6%
-491.4%
Net Margin
-316.0%
Revenue YoY
7.5%
179.2%
Net Profit YoY
-283.7%
EPS (diluted)
$0.00
$-2.45

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCRX
BCRX
HUT
HUT
Q1 26
$156.4M
Q4 25
$406.6M
$88.5M
Q3 25
$159.4M
$83.5M
Q2 25
$163.4M
$41.3M
Q1 25
$145.5M
$21.8M
Q4 24
$131.5M
$31.7M
Q3 24
$117.1M
$43.7M
Q2 24
$109.3M
$35.2M
Net Profit
BCRX
BCRX
HUT
HUT
Q1 26
Q4 25
$245.8M
$-279.7M
Q3 25
$12.9M
$50.1M
Q2 25
$5.1M
$137.3M
Q1 25
$32.0K
$-133.9M
Q4 24
$-26.8M
$152.2M
Q3 24
$-14.0M
$647.0K
Q2 24
$-12.7M
$-71.9M
Gross Margin
BCRX
BCRX
HUT
HUT
Q1 26
Q4 25
97.7%
60.4%
Q3 25
98.6%
61.3%
Q2 25
98.3%
47.3%
Q1 25
96.9%
14.5%
Q4 24
95.4%
35.9%
Q3 24
97.3%
59.9%
Q2 24
98.4%
41.4%
Operating Margin
BCRX
BCRX
HUT
HUT
Q1 26
13.6%
Q4 25
64.0%
-491.4%
Q3 25
18.6%
87.0%
Q2 25
18.2%
Q1 25
14.6%
-676.8%
Q4 24
-3.4%
Q3 24
6.6%
-3.6%
Q2 24
8.0%
-246.2%
Net Margin
BCRX
BCRX
HUT
HUT
Q1 26
Q4 25
60.5%
-316.0%
Q3 25
8.1%
60.0%
Q2 25
3.1%
332.5%
Q1 25
0.0%
-613.7%
Q4 24
-20.4%
480.3%
Q3 24
-12.0%
1.5%
Q2 24
-11.6%
-204.1%
EPS (diluted)
BCRX
BCRX
HUT
HUT
Q1 26
$0.00
Q4 25
$1.13
$-2.45
Q3 25
$0.06
$0.43
Q2 25
$0.02
$1.18
Q1 25
$0.00
$-1.30
Q4 24
$-0.13
$1.41
Q3 24
$-0.07
$0.01
Q2 24
$-0.06
$-0.78

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCRX
BCRX
HUT
HUT
Cash + ST InvestmentsLiquidity on hand
$259.0M
$44.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.4B
Total Assets
$465.1M
$2.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCRX
BCRX
HUT
HUT
Q1 26
$259.0M
Q4 25
$274.7M
$44.9M
Q3 25
$212.9M
$33.5M
Q2 25
$260.0M
$216.3M
Q1 25
$295.1M
$108.4M
Q4 24
$320.9M
$85.0M
Q3 24
$96.8M
Q2 24
$78.4M
Total Debt
BCRX
BCRX
HUT
HUT
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$300.6M
Q3 24
$297.3M
Q2 24
$328.8M
Stockholders' Equity
BCRX
BCRX
HUT
HUT
Q1 26
Q4 25
$-119.2M
$1.4B
Q3 25
$-387.9M
$1.4B
Q2 25
$-421.6M
$1.3B
Q1 25
$-451.9M
$960.0M
Q4 24
$-475.9M
$976.7M
Q3 24
$-468.6M
$703.9M
Q2 24
$-475.6M
$660.1M
Total Assets
BCRX
BCRX
HUT
HUT
Q1 26
$465.1M
Q4 25
$514.2M
$2.8B
Q3 25
$446.4M
$2.7B
Q2 25
$457.2M
$2.0B
Q1 25
$480.0M
$1.6B
Q4 24
$490.4M
$1.5B
Q3 24
$491.3M
$1.1B
Q2 24
$472.4M
$1.1B
Debt / Equity
BCRX
BCRX
HUT
HUT
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.31×
Q3 24
0.42×
Q2 24
0.50×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCRX
BCRX
HUT
HUT
Operating Cash FlowLast quarter
$-139.2M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCRX
BCRX
HUT
HUT
Q1 26
Q4 25
$292.0M
$-139.2M
Q3 25
$41.6M
$770.0K
Q2 25
$41.3M
$-48.8M
Q1 25
$-27.5M
$-33.8M
Q4 24
$-5.2M
$-68.5M
Q3 24
$8.2M
$-4.2M
Q2 24
$-1.4M
$-16.4M
Free Cash Flow
BCRX
BCRX
HUT
HUT
Q1 26
Q4 25
$291.2M
Q3 25
$40.3M
Q2 25
$41.1M
Q1 25
$-27.7M
Q4 24
$-5.9M
Q3 24
$8.2M
Q2 24
$-1.5M
FCF Margin
BCRX
BCRX
HUT
HUT
Q1 26
Q4 25
71.6%
Q3 25
25.3%
Q2 25
25.2%
Q1 25
-19.0%
Q4 24
-4.5%
Q3 24
7.0%
Q2 24
-1.4%
Capex Intensity
BCRX
BCRX
HUT
HUT
Q1 26
Q4 25
0.2%
Q3 25
0.8%
Q2 25
0.1%
Q1 25
0.1%
Q4 24
0.5%
Q3 24
0.1%
Q2 24
0.1%
Cash Conversion
BCRX
BCRX
HUT
HUT
Q1 26
Q4 25
1.19×
Q3 25
3.23×
0.02×
Q2 25
8.12×
-0.36×
Q1 25
-859.91×
Q4 24
-0.45×
Q3 24
-6.49×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCRX
BCRX

ORLADEYO$148.3M95%
Other revenues$5.0M3%
License revenue$3.0M2%

HUT
HUT

High Performance Computing Colocation And Cloud$81.9M93%
Power$5.0M6%
Digital Infrastructure$1.6M2%

Related Comparisons